Recombinant chimpanzee adenovirus type 155 HBV vaccine - GSK
Alternative Names: ChAd155-hIi-HBV; GSK-3528869; GSK-3528869ALatest Information Update: 28 Dec 2024
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class DNA vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Hepatitis-B(Treatment-experienced, In adults) in Hong Kong (IM, Injection)
- 26 Nov 2024 GSK terminates the phase I clinical trials in Hepatitis B in Germany, Belgium and United Kingdom, France, Hong Kong, Poland, Spain, Taiwan and Thailand due to the lack of efficacy and a priority on patient safety.(IM) (NCT03866187)
- 28 Apr 2022 No recent reports of development identified for phase-I development in Hepatitis-B in Belgium (IM, Injection)